A Comparative Study on Prophylactic Efficacy of Cinnarizine and Amitriptyline in Childhood Migraine: A Randomized Double-Blind Clinical Trial Publisher Pubmed



Olfat M¹ ; Hosseinpour S² ; Masoumi S³ ; Gogia Rastogi R⁴ ; Vance Hastriter E⁴ ; Lewis KS⁴ ; Little R⁴ ; T Karnik K⁴ ; Hickman C⁴ ; Heidari M² ; Shervin Badv R² ; Mohammadi M² ; Zamani GR² ; Mohammadpour M¹ Show All Authors
Source: Cephalalgia Published:2024

Abstract

Background: Pediatric migraine prophylaxis is indicated when headaches are frequent and/or disabling. We aimed to conduct a study to compare the efficacy of cinnarizine and amitriptyline in pediatric migraine prophylaxis. Methods: In a randomized, double-blind trial, patients aged 4–17 years with migraine who were eligible for prophylaxis enrolled. The primary outcome was a reduction response rate of ≥50% with p < 0.005 with respect to headache characteristics. The secondary outcome was migraine disability assessment. We evaluated patients every four weeks for three months: T1: week 4, T2: week 8 and T3: week 12. The safety profile was also assessed. Results: Thirty patients were randomly assigned to each group. However, 43 patients completed the trial. Headache frequency decreased in amitriptyline group more effectively in T1 (p = 0.004). Amitriptyline was more successful in reducing the headache duration in all three periods (p < 0.005). There was no significant difference in severity improvement and reducing disability score between the two groups (p > 0.005). No serious adverse events were observed. Conclusions: Both medications are effective in ameliorating migraine headaches and related disabilities. However, amitriptyline appears be a preferable option over cinnarizine, given its faster onset of action, efficacy in reducing headache duration and longer-lasting effects. Trial Registration: The study was registered with the Iranian Registry of Clinical Trials (IRCT) under the code IRCT-20191112045413N1. © International Headache Society 2024.